He overhauls ImClone Systems. Pushes MedImmune into the arms of AstraZeneca. And forces Biogen into play. Now, Carl The Raider may be going after Genzyme. Icahn Capital Management reported it owned 1.5 million shares of Genzyme stock as of Sept. 30, or less than 1 percent of the biotech, in a filing with the Securities and Exchange Commission, The Boston Globe reports.
